Trials / Completed
CompletedNCT00513175
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 44 (planned)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 16 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to examine transplant related mortality (TRM) at 100 days \<30%. A TRM of \>50% is considered unacceptable. This study also seeks a TRM at 12 months that is \<50%, engraftment \>90% (defined as donor cells \>80% at 6 months), and 1 year overall survival \>50%.
Conditions
- Acute Myeloid Leukemia
- Myelodysplasia
- Acute Lymphoblastic Leukemia
- Chronic Lymphocytic Leukemia
- Follicular Lymphoma
- Multiple Myeloma
- NHL
- Myeloproliferative Diseases
- Chronic Myeloid Leukemia
- Renal Cell Carcinoma
- Aplastic Anemia
Timeline
- Start date
- 2001-10-01
- Completion
- 2007-11-01
- First posted
- 2007-08-08
- Last updated
- 2012-11-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00513175. Inclusion in this directory is not an endorsement.